Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 15, Issue 6, Pages 314-322Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2014.09.007
Keywords
B cell lymphoma 2 inhibitors; Bruton tyrosine kinase inhibitors; CDK inhibitors; Immunomodulators; PI3K inhibitors
Categories
Ask authors/readers for more resources
Half of a century ago, physicians managing chronic lymphocytic leukemia (CLL) recognized some of its presenting features such as lymphocytosis, lymphadenopathy, and splenomegaly. Subsequently, an enhanced understanding of the disease mechanisms involved in CLL led to new, more targeted treatments. There is now a plethora of treatments available for CLL. In this review article we discuss in detail several of the novel agents that are being studied or approved for the treatment of CLL including: phosphatidylinositol 3-kinase inhibitors (idelalisib and IPI-145), Bruton tyrosine kinase inhibitors (ibrutinib), B cell lymphoma 2 inhibitors (ABT-263 and ABT-199), new anti-CD20 monoclonal antibodies (obinutuzumab), cyclin-dependent kinase inhibitors (flavopiridol and dinaciclib), immunomodulators (lenalidomide) and chimeric antigen receptor T-cell therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available